Dallas A Forshew1, Mark B Bromberg. 1. Department of Neurology, University of California San Francisco, San Francisco, CA 94117, USA. forshew@itsa.ucsf.edu
Abstract
UNLABELLED: Symptomatic management is the mainstay of ALS patient care, but there are few controlled trials of drugs and interventions for common symptoms. METHODS: We queried ALS clinic neurologists to determine drugs and interventions of choice and neurologists' perceived efficacy for 14 symptoms. RESULTS: The results are tabulations of the physicians' four most frequent choices for each symptom, the physicians' perception of efficacy, the average doses and average daily costs. A wide range of drugs and interventions were nominated for management of ALS symptoms. Consensus on treatment was rare for individual symptoms, and efficacy for any symptom was judged moderate at best. A few drugs were recommended for multiple symptoms. Comparisons of perceived efficacy compared to drug costs are informative. DISCUSSION: The results of the survey emphasize the challenges of symptom management in ALS. These data aid clinical management and guide rational choices for randomized controlled trials.
UNLABELLED: Symptomatic management is the mainstay of ALSpatient care, but there are few controlled trials of drugs and interventions for common symptoms. METHODS: We queried ALS clinic neurologists to determine drugs and interventions of choice and neurologists' perceived efficacy for 14 symptoms. RESULTS: The results are tabulations of the physicians' four most frequent choices for each symptom, the physicians' perception of efficacy, the average doses and average daily costs. A wide range of drugs and interventions were nominated for management of ALS symptoms. Consensus on treatment was rare for individual symptoms, and efficacy for any symptom was judged moderate at best. A few drugs were recommended for multiple symptoms. Comparisons of perceived efficacy compared to drug costs are informative. DISCUSSION: The results of the survey emphasize the challenges of symptom management in ALS. These data aid clinical management and guide rational choices for randomized controlled trials.
Authors: Carlayne E Jackson; April L McVey; Stacy Rudnicki; Mazen M Dimachkie; Richard J Barohn Journal: Neurol Clin Date: 2015-11 Impact factor: 3.806
Authors: Björn Oskarsson; Dan Moore; Tahseen Mozaffar; John Ravits; Martina Wiedau-Pazos; Nicholas Parziale; Nanette C Joyce; Ross Mandeville; Namita Goyal; Merit E Cudkowicz; Michael Weiss; Robert G Miller; Craig M McDonald Journal: Muscle Nerve Date: 2018-03-06 Impact factor: 3.217
Authors: Deanna Britton; Joshua O Benditt; Albert L Merati; Robert M Miller; Cara E Stepp; Louis Boitano; Amanda Hu; Marcia A Ciol; Kathryn M Yorkston Journal: Dysphagia Date: 2014-07-19 Impact factor: 3.438
Authors: James B Caress; Stephanie L Ciarlone; Elizabeth A Sullivan; Leah P Griffin; Michael S Cartwright Journal: Muscle Nerve Date: 2015-09-28 Impact factor: 3.217